Drug intelligence / Profile preview

TJ012

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Small Molecules

Overview

TJ012 is an investigational small molecule drug candidate being developed by Tuojie Biotech (拓界生物医药) for the treatment of tumors. It is currently positioned in the company's research and development pipeline within the oncology therapeutic area. As of early 2024, Tuojie Biotech has not publicly disclosed the specific molecular target or the detailed mechanism of action for TJ012. The drug is part of a portfolio that includes both small molecules and small nucleic acid (siRNA) therapies, often developed in collaboration or associated with assets from larger pharmaceutical entities like Hengrui.

Beyond the preview

Go deeper on TJ012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ012.

Explore the full profile